Strides Pharma Expands Footprint in Africa with Strategic Sandoz Deal
Strides Pharma Science has entered into an agreement with Sandoz AG to acquire several branded generic products in Sub-Saharan Africa. The deal, valued at USD 12 million, covers key markets including Ghana, Nigeria, and Kenya. The transaction is expected to close by the end of Q2 FY27.
- Country:
- India
Strides Pharma Science announced a pivotal deal with Sandoz AG to purchase selected branded generic products throughout Sub-Saharan Africa. This move, costing USD 12 million upfront, signifies a substantial expansion for Strides.
The definitive agreements, anticipated for completion by Q2 FY27, highlight a strategic push into vital markets like Western Sahara, Ghana, Nigeria, and Kenya. These areas are pivotal, illustrating a broadened scope for Strides' operations.
The acquisition, focused on therapeutic sectors such as anti-infective, cardiovascular, and dermatology, is poised to cement Strides as a major pharmaceutical player in the region, potentially ranking it among the leading firms by sales in Sub-Saharan Africa.
Google News